GRAIL (NASDAQ:GRAL) Shares Gap Down – Here’s What Happened

Posted by Brian Himes on Nov 7th, 2026

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $143.66, but opened at $119.50. GRAIL shares last traded at $127.3850, with a volume of 234,323 shares.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

Positive Sentiment: Royal Bank of Canada raised its price target to $100 from $84, signaling a more favorable valuation view than before, although it kept a “sector perform” rating. RBC target update
Neutral Sentiment: Goldman Sachs assigned GRAIL a “Hold,” and RBC also maintained its “Hold” view, reflecting a wait-and-see stance rather than a strong near-term catalyst. Goldman Sachs rating RBC rating
Negative Sentiment: RBC’s new $100 target remains below the stock’s recently quoted $121.44 price, implying the analyst sees limited upside at that level despite the increase in its estimate. RBC target update
Negative Sentiment: GRAIL is cutting Galleri prices to support adoption ahead of an expected early-2027 FDA decision, but lower pricing could weigh on revenue growth and margins. Its latest quarter also showed revenue of $37.54 million below the $44.21 million consensus estimate, despite a smaller-than-expected per-share loss. Q3 pricing and FDA outlook Q3 financial results

Wall Street Analyst Weigh In

Several research firms recently weighed in on GRAL. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Guggenheim upped their target price on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Robert W. Baird increased their target price on GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research report on Tuesday, September 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. Finally, Morgan Stanley boosted their price target on GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and an average target price of $121.40.

Read Our Latest Report on GRAIL

GRAIL Trading Up 1.9%

The business’s 50-day simple moving average is $117.15 and its two-hundred day simple moving average is $79.33. The firm has a market cap of $5.42 billion, a price-to-earnings ratio of -12.78 and a beta of 2.86.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($2.21) EPS for the quarter, beating analysts’ consensus estimates of ($2.45) by $0.24. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $37.53 million for the quarter, compared to analyst estimates of $44.21 million. On average, analysts forecast that GRAIL, Inc. will post -10.07 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In related news, insider Andrew Partridge sold 7,873 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the sale, the insider owned 155,865 shares in the company, valued at $22,817,077.35. This represents a 4.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Aaron Freidin sold 23,619 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the sale, the chief financial officer directly owned 225,364 shares of the company’s stock, valued at $32,991,035.96. This represents a 9.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 129,944 shares of company stock valued at $14,832,805. 1.83% of the stock is currently owned by insiders.

Institutional Trading of GRAIL

Large investors have recently modified their holdings of the stock. Aberdeen Group plc grew its stake in shares of GRAIL by 25.6% in the 3rd quarter. Aberdeen Group plc now owns 288,249 shares of the company’s stock valued at $40,389,000 after buying an additional 58,746 shares during the period. Moors & Cabot Inc. bought a new stake in shares of GRAIL during the third quarter valued at approximately $242,000. Russell Investments Group Ltd. raised its position in shares of GRAIL by 91.0% during the third quarter. Russell Investments Group Ltd. now owns 54,246 shares of the company’s stock worth $7,601,000 after purchasing an additional 25,843 shares during the period. Pier 88 Investment Partners LLC acquired a new position in shares of GRAIL during the third quarter worth approximately $504,000. Finally, Brighton Jones LLC bought a new position in shares of GRAIL in the 3rd quarter worth $219,000.

About GRAIL

(Get Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.